Position ahead of summer 2026 data readout, which could validate NBD1 stabilization as a new mechanism in CF. Monitor for signs of clinical differentiation, especially in sweat chloride reduction beyond Trikafta alone. Given recent insider selling of $50.8M, assess management conviction at data release.
Price Chart
Executive Summary
Sionna Therapeutics announced completion of patient enrollment in its Phase 2a PreciSION CF trial evaluating SION-719, a first-in-class NBD1 stabilizer, in cystic fibrosis patients on Trikafta. Topline data is expected in summer 2026, marking a key clinical catalyst for the company's novel CFTR-targeting approach.
Key Facts
- Completed enrollment in Phase 2a PreciSION CF trial for SION-719, a first-in-class NBD1 stabilizer.
- Trial evaluates SION-719 added to Trikafta in F508del-homozygous CF patients using a crossover design.
- Primary endpoints include safety, pharmacokinetics, and change in sweat chloride levels (a biomarker of CFTR function).
- Topline data expected in summer 2026, representing a near-term clinical readout.
- Trial conducted across sites in the CF Foundation’s Therapeutics Development Network.
Financial Impact
No direct financial impact disclosed; clinical milestone de-risking potential ahead of data readout.
Risk Factors
- Clinical failure risk: No guarantee that SION-719 will show meaningful improvement in sweat chloride or safety.
- High valuation sensitivity: With $1.7B market cap and no approved products, stock is highly dependent on clinical execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281460 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $4.50 $7.30 | ▼ −62.22% | ▼ −63.14% | $5.04 (−12.00%) |
Aug 6, 2026 8w ago | 8-K | $49.61 $6.75 | ▼ −86.39% | ▼ −86.99% | $5.04 (−89.84%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▲ +12.70% | ▲ +10.27% | $5.04 (−88.87%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▼ −12.70% | ▼ −10.27% | $5.04 (+88.87%) |
Jul 7, 2026 12w ago | Insider Cluster | $44.00 $47.34 | ▼ −7.59% | ▼ −4.32% | $5.04 (+88.55%) |
Jul 2, 2026 13w ago | Insider Cluster | $43.99 $46.78 | ▲ +6.34% | ▲ +6.76% | $5.04 (−88.54%) |
Jun 11, 2026 16w ago | Institutional Cluster | $36.05 $44.94 | ▲ +24.66% | ▲ +22.77% | $5.04 (−86.02%) |
May 30, 2026 17w ago | Insider Cluster | $40.90 $43.99 | ▲ +7.55% | ▲ +8.85% | $5.04 (−87.68%) |
May 29, 2026 17w ago | 144 | $40.90 $43.99 | ▼ −7.55% | ▼ −8.85% | $5.04 (+87.68%) |
May 12, 2026 20w ago | 8-K | $40.94 $34.03 | ▼ −16.88% | ▼ −15.15% | $5.04 (−87.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access